% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kersting:277883,
      author       = {D. Kersting$^*$ and P. Sandach$^*$ and M. Sraieb$^*$ and M.
                      Wiesweg$^*$ and M. Metzenmacher$^*$ and K. Darwiche and F.
                      Oezkan and S. Bölükbas and M. Stuschke$^*$ and L.
                      Umutlu$^*$ and M. Nader$^*$ and R. Hamacher$^*$ and W. P.
                      Fendler$^*$ and J. Wienker and W. E. E. Eberhardt$^*$ and M.
                      Schuler$^*$ and K. Herrmann$^*$ and H. Hautzel$^*$},
      title        = {68{G}a-{SSO}-120 {PET} for {I}nitial {S}taging of {S}mall
                      {C}ell {L}ung {C}ancer {P}atients: {A} {S}ingle-{C}enter
                      {R}etrospective {S}tudy.},
      journal      = {Journal of nuclear medicine},
      volume       = {64},
      number       = {10},
      issn         = {0097-9058},
      address      = {New York, NY},
      publisher    = {Soc.},
      reportid     = {DKFZ-2023-01551},
      pages        = {1540-1549},
      year         = {2023},
      note         = {2023 Oct;64(10):1540-1549},
      abstract     = {PET imaging using the somatostatin receptor 2 (SSTR2)
                      antagonist satoreotide trizoxetan (SSO-120, previously
                      OPS-202) could offer accurate tumor detection and screening
                      for SSTR2-antagonist radionuclide therapy in patients with
                      SSTR2-expressing small cell lung cancer (SCLC). The aim of
                      this single-center study was to investigate tumor uptake and
                      detection rates of 68Ga-SSO-120 in comparison to 18F-FDG PET
                      in the initial staging of SCLC patients. Methods: Patients
                      with newly diagnosed SCLC who underwent additional
                      whole-body 68Ga-SSO-120 PET/CT during the initial diagnostic
                      workup were retrospectively included. The mean administered
                      activity was 139 MBq, and the mean uptake time was 60 min.
                      Gold-standard staging 18F-FDG PET/CT was evaluated if
                      available within 2 wk before or after 68Ga-SSO-120 PET if
                      morphologic differences in CT images were absent.
                      68Ga-SSO-120- or 18F-FDG-positive lesions were reported in 7
                      anatomic regions (primary tumor, thoracic lymph node
                      metastases, and distant metastases including pleural,
                      contralateral pulmonary, liver, bone, and other) according
                      to the TNM classification for lung cancer (eighth edition).
                      Consensus TNM staging (derived from CT, endobronchial
                      ultrasound-guided transbronchial needle aspiration, PET, and
                      brain MRI) by a clinical tumor board served as the reference
                      standard. Results: Thirty-one patients were included, 12
                      with limited and 19 with extensive disease according to the
                      Veterans Administration Lung Study Group classification.
                      68Ga-SSO-120-positive tumor was detected in all patients
                      $(100\%)$ and in 90 of the 217 evaluated regions $(41.5\%).$
                      Thirteen patients $(42.0\%)$ had intense average
                      68Ga-SSO-120 uptake (region-based mean SUVmax ≥ 10); 28
                      patients $(90.3\%)$ had average 68Ga-SSO-120 uptake greater
                      than liver uptake (region-based mean peak tumor-to-liver
                      ratio > 1). In 25 patients with evaluable 18F-FDG PET,
                      primary tumor, thoracic lymph node metastases, and distant
                      metastases were detected in $100\%,$ $92\%,$ and $64\%,$
                      respectively, of all investigated patients by 68Ga-SSO-120
                      and in $100\%,$ $92\%,$ and $56\%,$ respectively, by 18F-FDG
                      PET. 68Ga-SSO-120 PET detected additional contralateral
                      lymph node, liver, and brain metastases in 1, 1, and 2
                      patients, respectively (no histopathology available), and
                      18F-FDG PET detected additional contralateral lymph node
                      metastases in 3 patients (1 confirmed, 1 systematic
                      endobronchial ultrasound-guided transbronchial needle
                      aspiration-negative, and 1 without available
                      histopathology). None of these differences altered Veterans
                      Administration Lung Study Group staging. The region-based
                      monotonic correlation between 68Ga-SSO-120 and 18F-FDG
                      uptake was low (Spearman ρ = 0.26-0.33). Conclusion:
                      68Ga-SSO-120 PET offers high diagnostic precision with
                      comparable detection rates and additional complementary
                      information to the gold standard, 18F-FDG PET. Consistent
                      uptake in most patients warrants exploration of
                      SSTR2-directed radionuclide therapy.},
      keywords     = {68Ga-OPS-202 (Other) / 68Ga-SSO-120 (Other) / PET (Other) /
                      SCLC (Other) / SSTR (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37474272},
      doi          = {10.2967/jnumed.123.265664},
      url          = {https://inrepo02.dkfz.de/record/277883},
}